Clinical Trial Update: Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the termination of a Phase 1/2 study evaluating MLN8237 in combination with erlotinib for non-small cell lung cancer, includi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• MLN8237 (alisertib) (alisertib)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent | Phase 1, Phase 2 | Status: TERMINATED